头颈部微血管游离组织移植重建在慢性药物免疫抑制状态下的安全性
该回顾性队列研究在两家三级转诊中心于2016年8月至2020年5月开展,979例接受头颈部微血管游离组织移植(MVFTT)重建的患者中47例(5%)使用慢性免疫抑制药物。免疫抑制最常见指征为实体器官移植和自身免疫病。14例(30%)在术后30天内出现手术并发症,包括8例(17%)伤口裂开、6例(12%)血肿和2例(4%)手术部位感染,1例完全和1例部分皮瓣失败,30天再手术率为4%。结论认为MVFTT在此类患者中似乎是安全的。
要点
- 979例MVFTT患者中47例(5%)接受慢性免疫抑制药物治疗。
- 免疫抑制最常见指征为实体器官移植和自身免疫病。
- 30天内手术并发症14例(30%):伤口裂开8例(17%)、血肿6例(12%)、手术部位感染2例(4%)。
核心结论
- 头颈部MVFTT在慢性药物免疫抑制患者中似乎是安全的。
研究设计与样本
- 回顾性队列研究,于2016年8月至2020年5月在两家三级转诊中心开展。
- 共979例患者接受MVFTT,其中47例(5%)使用慢性免疫抑制药物。
主要发现
- 免疫抑制最常见指征为实体器官移植和自身免疫病。
- 术后30天内手术并发症14例(30%):伤口裂开8例(17%)、血肿6例(12%)、手术部位感染2例(4%)。
- 1例完全和1例部分皮瓣失败,30天再手术率为4%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients on chronic pharmacologic immunosuppressive therapy are at increased risk of wound infection and complications after surgery. There is a paucity of data examining perioperative complications after microvascular free tissue transfer (MVFTT) reconstruction of the head and neck in this patient population. METHODS: Retrospective cohort study performed at two tertiary referral centers between August 2016 and May 2020. RESULTS: Nine hundred and seventy-nine patients underwent MVFTT during the study period; of these 47 (5%) patients were taking chronic immunosuppressive medications. The most common indications for immunosuppression were solid organ transplant and autoimmune disease. Fourteen (30%) patients had surgical complications within 30 days of surgery: 8 (17%) wound dehiscences, 6 (12%) hematomas, and 2 (4%) surgical site infections. There was one total and one partial flap failure with a 30-day reoperation rate of 4%. CONCLUSIONS: MVFTT of the head and neck appears to be safe in patients on chronic pharmacologic immunosuppression.
引用
- Wang R, Horwich P, Sandulache VC, et al. Safety of microvascular free tissue transfer reconstruction of the head and neck in the setting of chronic pharmacologic immunosuppression. Head Neck. 2022. PMID: 35437907. doi:10.1002/hed.27049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。